Nov, 2022

U.S.A.
News / Therapeutic Area News
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction (GEJ) Cancers
Astellas' SPOTLIGHT trial meets primary endpoint of progression-free survival (PFS) Full data to be presented at future scientific congress TOKYO, Nov. 17, 2022 /PRNewswire/ -- Astellas Pharma...
Read More

Oct, 2022

U.S.A.
News / Therapeutic Area News
Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting
SKYLIGHT 4™ study results demonstrate the 52-week safety and tolerability of fezolinetant 30 mg and 45 mg once daily Pooled analyses will also be presented from SKYLIGHT 1™ and SKYLIGHT 2™...
Read More

Sep, 2022

U.S.A.
News / Therapeutic Area News
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant
If authorized by the European Commission, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause TOKYO, Sept. 29, 2022 /PRNewswire/ --...
Read More

Aug, 2022

U.S.A.
News / Therapeutic Area News
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant
If approved by the FDA, fezolinetant would be a nonhormonal treatment for moderate to severe vasomotor symptoms associated with menopause TOKYO, Aug. 18, 2022 /PRNewswire/ -- Astellas Pharma Inc....
Read More

Jul, 2022

U.S.A.
News / Therapeutic Area News
Astellas and Seagen Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
– Companies plan to discuss results with regulatory authorities – TOKYO and BOTHELL, Wash., July 26, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa,...
Read More